Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Bernsdorf, Mogens ; Ingvar, Christian ; Jörgensen, Leif ; Tuxen, Malgorzata K ; Jakobsen, Poul Erik ; Saetersdal, Anna ; Kimper-Karl, Marie Louise ; Kroman, Niels ; Balslev, Eva ; Ejlertsen, Bent. / Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial. I: Breast Cancer Research and Treatment. 2011 ; Bind 126, Nr. 2. s. 463-70.

Bibtex

@article{0ead8ef84422446d974271cd59c2822c,
title = "Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial",
abstract = "Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, has shown both anti-proliferative and anti-tumoral activity in breast cancer. This study was designed to determine the effect of adding gefitinib to neoadjuvant epirubicin and cyclophosphamide (EC) on tumor response rates. Women with unilateral, primary operable, estrogen receptor negative invasive breast cancer ≥ 2 cm were eligible for inclusion. Randomized patients were to receive four cycles of neoadjuvant EC plus 12 weeks of either gefitinib (250 mg daily) or placebo. Primary endpoint was pathologic complete response (pCR), and secondary endpoints were complete response (CR) and overall objective response (OR). 181 patients were randomized. A pCR was observed in 17{\%} (12/71) of patients treated with gefitinib and in 12{\%} (9/73) of patients treated with placebo (4.57{\%} difference, 95{\%} CI -7.19 to 6.33; P = 0.44). CR was observed in 10{\%} of patients in both the gefitinib (7/71) and the placebo group (7/73) (0.27{\%} difference, 95{\%} CI -9.6 to 10.2; P = 0.96). There was no significant difference in OR (5.96{\%}; 95{\%} CI -9.9 to 21.9; P = 0.45) between the two groups. Post hoc subgroup analysis showed a significant difference in pCR between triple negative breast cancer (TNBC) and non-TNBC tumors (P = 0.03). More patients in the gefitinib arm had hematological toxicity (P = 0.15) and discontinued treatment (9/94 vs. 2/86) because of adverse events (AE). Tumor response rates were similar in the two groups. A significantly higher pCR rate was observed post hoc in TNBC versus non-TNBC independent of treatment. More patients in the gefitinib group discontinued treatment because of AE.",
keywords = "Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Carcinoma, Ductal, Breast, Carcinoma, Lobular, Cyclophosphamide, Double-Blind Method, Epirubicin, Female, Fever, Humans, Leukopenia, Middle Aged, Neoadjuvant Therapy, Neutropenia, Quinazolines, Receptors, Estrogen, Research Design, Treatment Outcome, Tumor Burden",
author = "Mogens Bernsdorf and Christian Ingvar and Leif J{\"o}rgensen and Tuxen, {Malgorzata K} and Jakobsen, {Poul Erik} and Anna Saetersdal and Kimper-Karl, {Marie Louise} and Niels Kroman and Eva Balslev and Bent Ejlertsen",
year = "2011",
doi = "10.1007/s10549-011-1352-2",
language = "English",
volume = "126",
pages = "463--70",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York LLC",
number = "2",

}

RIS

TY - JOUR

T1 - Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial

AU - Bernsdorf, Mogens

AU - Ingvar, Christian

AU - Jörgensen, Leif

AU - Tuxen, Malgorzata K

AU - Jakobsen, Poul Erik

AU - Saetersdal, Anna

AU - Kimper-Karl, Marie Louise

AU - Kroman, Niels

AU - Balslev, Eva

AU - Ejlertsen, Bent

PY - 2011

Y1 - 2011

N2 - Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, has shown both anti-proliferative and anti-tumoral activity in breast cancer. This study was designed to determine the effect of adding gefitinib to neoadjuvant epirubicin and cyclophosphamide (EC) on tumor response rates. Women with unilateral, primary operable, estrogen receptor negative invasive breast cancer ≥ 2 cm were eligible for inclusion. Randomized patients were to receive four cycles of neoadjuvant EC plus 12 weeks of either gefitinib (250 mg daily) or placebo. Primary endpoint was pathologic complete response (pCR), and secondary endpoints were complete response (CR) and overall objective response (OR). 181 patients were randomized. A pCR was observed in 17% (12/71) of patients treated with gefitinib and in 12% (9/73) of patients treated with placebo (4.57% difference, 95% CI -7.19 to 6.33; P = 0.44). CR was observed in 10% of patients in both the gefitinib (7/71) and the placebo group (7/73) (0.27% difference, 95% CI -9.6 to 10.2; P = 0.96). There was no significant difference in OR (5.96%; 95% CI -9.9 to 21.9; P = 0.45) between the two groups. Post hoc subgroup analysis showed a significant difference in pCR between triple negative breast cancer (TNBC) and non-TNBC tumors (P = 0.03). More patients in the gefitinib arm had hematological toxicity (P = 0.15) and discontinued treatment (9/94 vs. 2/86) because of adverse events (AE). Tumor response rates were similar in the two groups. A significantly higher pCR rate was observed post hoc in TNBC versus non-TNBC independent of treatment. More patients in the gefitinib group discontinued treatment because of AE.

AB - Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, has shown both anti-proliferative and anti-tumoral activity in breast cancer. This study was designed to determine the effect of adding gefitinib to neoadjuvant epirubicin and cyclophosphamide (EC) on tumor response rates. Women with unilateral, primary operable, estrogen receptor negative invasive breast cancer ≥ 2 cm were eligible for inclusion. Randomized patients were to receive four cycles of neoadjuvant EC plus 12 weeks of either gefitinib (250 mg daily) or placebo. Primary endpoint was pathologic complete response (pCR), and secondary endpoints were complete response (CR) and overall objective response (OR). 181 patients were randomized. A pCR was observed in 17% (12/71) of patients treated with gefitinib and in 12% (9/73) of patients treated with placebo (4.57% difference, 95% CI -7.19 to 6.33; P = 0.44). CR was observed in 10% of patients in both the gefitinib (7/71) and the placebo group (7/73) (0.27% difference, 95% CI -9.6 to 10.2; P = 0.96). There was no significant difference in OR (5.96%; 95% CI -9.9 to 21.9; P = 0.45) between the two groups. Post hoc subgroup analysis showed a significant difference in pCR between triple negative breast cancer (TNBC) and non-TNBC tumors (P = 0.03). More patients in the gefitinib arm had hematological toxicity (P = 0.15) and discontinued treatment (9/94 vs. 2/86) because of adverse events (AE). Tumor response rates were similar in the two groups. A significantly higher pCR rate was observed post hoc in TNBC versus non-TNBC independent of treatment. More patients in the gefitinib group discontinued treatment because of AE.

KW - Adult

KW - Aged

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Breast Neoplasms

KW - Carcinoma, Ductal, Breast

KW - Carcinoma, Lobular

KW - Cyclophosphamide

KW - Double-Blind Method

KW - Epirubicin

KW - Female

KW - Fever

KW - Humans

KW - Leukopenia

KW - Middle Aged

KW - Neoadjuvant Therapy

KW - Neutropenia

KW - Quinazolines

KW - Receptors, Estrogen

KW - Research Design

KW - Treatment Outcome

KW - Tumor Burden

U2 - 10.1007/s10549-011-1352-2

DO - 10.1007/s10549-011-1352-2

M3 - Journal article

VL - 126

SP - 463

EP - 470

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 2

ER -

ID: 33154419